The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase Ib trial combining rapid determination of drug-drug interaction (DDI) followed by a dose finding period to assess safety and preliminary efficacy of fimepinostat plus venetoclax in patients with aggressive B-cell lymphoma.
 
Tycel Jovelle Phillips
Honoraria - Bayer; Genentech; Gilead Sciences; Incyte; Pharmacyclics; Seagen
Consulting or Advisory Role - Bayer; Curis; Genentech; Gilead Sciences; Gilead Sciences; Incyte; Pharmacyclics; Seagen
Research Funding - Abbvie; Bayer; Pharmacyclics/Janssen
 
Sven De Vos
No Relationships to Disclose
 
Jason Westin
Consulting or Advisory Role - Amgen; Celgene; Curis; Genentech/Abbvie; Janssen Scientific Affairs; Juno Therapeutics; Juno Therapeutics; Kite/Gilead; MorphoSys; Novartis
Research Funding - Bristol-Myers Squibb; Celgene; Curis; Genentech; Janssen; Kite/Gilead; Novartis
 
Stefan K. Barta
Honoraria - Mundipharma
Consulting or Advisory Role - Janssen Oncology; Seagen
Research Funding - Bayer (Inst); Celgene; Merck; Seagen; Takeda
Travel, Accommodations, Expenses - Curis
 
Jonathon Brett Cohen
Consulting or Advisory Role - Abbvie; Aptitude Medical; AstraZeneca; Celgene; Cellectar; Janssen; Kite/Gilead; Loxo; Seagen
Research Funding - AI Therapeutics (Inst); ASH (Inst); AstraZeneca (Inst); Bioinvent (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Janssen (Inst); Loxo (Inst); Lymphoma Research Foundation (Inst); Novartis (Inst); Takeda (Inst)
 
Krish Patel
Honoraria - Dava Oncology
Consulting or Advisory Role - AstraZeneca; BeiGene; Celgene; Genentech; Juno Therapeutics; Pharmacyclics
Speakers' Bureau - AstraZeneca; Celgene; Genentech; Pharmacyclics/Janssen
Research Funding - Aptevo Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Curis (Inst); Kite/Gilead (Inst); MEI Pharma (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Sunesis Pharmaceuticals (Inst); Takeda (Inst); Trillium Therapeutics (Inst); Xencor (Inst)
 
Sonali M. Smith
Consulting or Advisory Role - Abbvie/Genentech; AstraZeneca; Bayer; Bristol-Myers Squibb; Celgene; Gilead Sciences; Kite, a Gilead company; Pharmacyclics; Portola Pharmaceuticals; Seagen; TG Therapeutics
Research Funding - Acerta Pharma/AstraZeneca; Celgene; Pharmacyclics/Janssen
 
John M. Pagel
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; Gilead Sciences; Pharmacyclics
 
Vikram Kansra
No Relationships to Disclose
 
Dena Grayson
Consulting or Advisory Role - BioCryst; Curis
Travel, Accommodations, Expenses - BioCryst; Curis
 
Anas Younes
Honoraria - Abbvie; Curis; Epizyme; Janssen; Merck; Roche; Takeda
Consulting or Advisory Role - Bio-Path Holdings, Inc; Celgene; Epizyme; HCM; Roche; Xynomic Pharma
Research Funding - Bristol-Myers Squibb (Inst); Curis (Inst); Genentech (Inst); Janssen (Inst); Merck (Inst); Roche (Inst); Syndax (Inst)
 
Connie Lee Batlevi
Honoraria - Dava Oncology
Consulting or Advisory Role - Celgene; Gerson Lehrman Group; Juno Therapeutics; Kite, a Gilead company; Lifesci Capital; Lifesci Capital; Seagen
Research Funding - Bayer (Inst); Epizyme; Janssen Biotech; Novartis; Xynomic Pharma